# A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics

> **NCT03099330** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** TQ-B3139

## Key facts

- **NCT ID:** NCT03099330
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-19
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03099330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03099330, "A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03099330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*